# Digital Diagnostics

> Digital Diagnostics is a Coralville, Iowa healthcare AI company that builds autonomous - not assistive - diagnostic systems that make a clinical decision without a physician reviewing the result. Its flagship product, LumineticsCore (formerly IDx-DR), was the first medical device of any kind to receive FDA authorization to make an autonomous diagnosis: it screens for diabetic retinopathy from retinal images at the point of care in primary care offices, no eye specialist required. Founded in 2010 by retina specialist and computer engineer Dr. Michael Abramoff, the company has raised more than $130 million to expand autonomous AI into new disease areas.

- **Founded:** 2010
- **Headquarters:** Coralville, Iowa, United States
- **Founders:** Michael D. Abramoff (Founder & Executive Chairman), John Bertrand (Co-Founder & CEO), Seth Rainford (Co-Founder & President/COO)
- **Team size:** ~71 employees (reported range 51-200)
- **Products:** LumineticsCore (formerly IDx-DR), DermSpot, SphereDx
- **Notable:** First company ever to receive FDA authorization for an autonomous AI diagnostic system (IDx-DR, 2018)., LumineticsCore is the first FDA-cleared AI to make a diagnosis without a physician reviewing the result., Raised more than $130 million, including a $75M Series B led by KKR in 2022.

## Products & services

- **LumineticsCore (formerly IDx-DR)** — FDA-cleared autonomous AI system that diagnoses diabetic retinopathy, including diabetic macular edema, from retinal camera images at the point of care in about 30 seconds - without a specialist reviewing the images. Deployed on the Topcon NW400 fundus camera.
- **DermSpot** — Autonomous AI system for skin condition diagnosis, extending the company's autonomous-diagnosis platform beyond the eye.
- **SphereDx** — Securely hosted platform for delivering and managing diagnostic results across care settings.

## Achievements

- First company ever to receive FDA authorization for an autonomous AI diagnostic system (IDx-DR, 2018).
- LumineticsCore is the first FDA-cleared AI to make a diagnosis without a physician reviewing the result.
- Raised more than $130 million, including a $75M Series B led by KKR in 2022.
- Deployed across numerous U.S. health systems and community clinics, with peer-reviewed evidence on real-world adoption.
- Named a 2024 Technology Association of Iowa 'Catalysts' honoree.
- Pioneered a biomarker-based, explainable approach to autonomous clinical AI that took on medical liability for its diagnoses.

## Latest updates

- **2024-01** — Named a 2024 Technology Association of Iowa 'Catalysts' honoree.
- **2023-01** — Rebranded flagship product IDx-DR to LumineticsCore.
- **2022-08** — Closed $75M Series B led by KKR, bringing total raised past $130M.
- **2022-02** — Announced partnership with Baxter International to advance diabetic retinopathy detection.

## Links

- Website: https://www.digitaldiagnostics.com
- LinkedIn: https://www.linkedin.com/company/digital-diagnostics
- Facebook: https://www.facebook.com/AItheRightWay

---

Profile page: https://yespress.io/digital-diagnostics
Published by YesPress — https://yespress.io
Last updated: 2026-07-12